<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01456507</url>
  </required_header>
  <id_info>
    <org_study_id>B4531003</org_study_id>
    <nct_id>NCT01456507</nct_id>
  </id_info>
  <brief_title>Healthy Volunteers Study to Estimate the Effects of Food on the Bioavailability of Oxycodone and Naltrexone/6- Β -Naltrexol From a Extended Release Formulation of Oxycodone With Sequestered Naltrexone</brief_title>
  <official_title>An Open-Label, Single-Dose, Randomized, Three-Way Crossover Study in Healthy Volunteers to Estimate the Effects of Food and of Sprinkling ALO-02 Pellets on Applesauce on the Bioavailability of Oxycodone and Naltrexone/6- Β -Naltrexol From a Extended Release Pellets-in-Capsule Formulation of Oxycodone 40 Mg With Sequestered Naltrexone 4.8 Mg</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to estimate the effects of food and of sprinkling ALO-02 pellets
      on applesauce on the bioavailability of oxycodone and naltrexone/6- beta-naltrexol from an
      extended release pellets-in-capsule formulation of oxycodone 40 mg with sequestered
      naltrexone 4.8 mg.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bioavailability
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve (AUC) to time infinity (inf) of oxycodone</measure>
    <time_frame>predose, 0.5,1,2,4,6,8,12,14,16,24,36,48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve (AUC) to last quantifiable concentration (last) of oxycodone</measure>
    <time_frame>predose, 0.5,1,2,4,6,8,12,14,16,24,36,48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of oxycodone</measure>
    <time_frame>predose, 0.5,1,2,4,6,8,12,14,16,24,36,48 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>C24, Tmax (time at maximum concentration) and half-life of oxycodone, as data permit.</measure>
    <time_frame>predose, 0.5,1,2,4,6,8,12,14,16,24,36,48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast, AUCinf, and Cmax of naltrexone and 6-beta-naltrexol, as data permit</measure>
    <time_frame>predose, 1,2,4,8,12,24,48,120 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events, vital signs, pulse oximetry, and safety laboratory parameters.</measure>
    <time_frame>over 120 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1×40 mg ALO-02 capsule administered with 240 mL of water under fasting conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1×40 mg ALO-02 capsule administered with 240 mL of water under fed conditions (standard high fat breakfast).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1×40 mg ALO-02 with the ALO-02 pellets sprinkled approximately on one table spoon of applesauce, and administered with 240 mL of water under fasting conditions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALO-02 (Oxycodone Naltrexone)</intervention_name>
    <description>single dose of ALO-02 capsule under fasting condition</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALO-02 (Oxycodone Naltrexone)</intervention_name>
    <description>single dose of ALO-02 capsule under fed condition</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALO-02 (Oxycodone Naltrexone)</intervention_name>
    <description>ALO-02 with the ALO-02 pellets sprinkled on applesauce, and administered under fasting conditions.</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive

        Exclusion Criteria:

          -  Evidence or history of clinically significant diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2011</study_first_submitted>
  <study_first_submitted_qc>October 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2011</study_first_posted>
  <last_update_submitted>January 12, 2012</last_update_submitted>
  <last_update_submitted_qc>January 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Food effect</keyword>
  <keyword>bioavailability</keyword>
  <keyword>oxycodone</keyword>
  <keyword>sequestered Naltrexone</keyword>
  <keyword>management of moderate to severe pain</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

